Current diagnostic tools and (chemo)therapies have not been effective in improving patient outcomes with advanced/metastatic PDA, a genetic disease commonly caused by oncogenic KRAS mutations, G12D (~50%) and G12V (~30%), respectively. This evidence concerns the gene KRAS and Patent ductus arteriosus.